MONTREAL, Sept. 26, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13, 2022.
The conference call will be held at 8:30 a.m. (ET) on October 13, 2022 to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Joining Mr. Lévesque on the call will be other members of the management team, including Chief Financial Officer Philippe Dubuc and Chief Medical Officer Christian Marsolais, who will be available to answer questions from participants following prepared remarks.
Participants are encouraged to join the call at least ten minutes in advance to secure access.
Conference call dial-in and replay information is below:
CONFERENCE CALL INFORMATION | |
Conference Call Date: | October 13, 2022 |
Conference Call Time: | 8:30 AM ET |
North America Dial-in: | 1- 877-513-4119 |
International Dial-in: | 1- 412-902-6615 |
Access Code: | 0675980 |
CONFERENCE CALL REPLAY | |
North America Dial-in: | 1- 877-344-7529 |
International Dial-in: | 1- 412-317-0088 |
Replay Access Code: | 1261932 |
Replay End Date | October 20, 2022 |
The live conference call will be accessible via webcast at: https://edge.media-server.com/mmc/p/69eduxxu
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Investors:
Elif McDonald
Senior Director, Investor Relations
1-438-315-8563
ir@theratech.com
Media Contact:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800
Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…
Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…
Proven healthcare executive and life sciences strategist joins to bring groundbreaking BioFuse Multi-Tissue Welder (MTW)…
Next Generation Shaw Scalpel Receives 510(k) Clearance, Ushering in a New Era of Surgical PrecisionKALAMAZOO,…
RAHWAY, NJ / ACCESSWIRE / March 26, 2024 / The Merck Foundation, a private charitable…
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Dr. Thomas Odeny grew up in…